Business
Achieve Life Sciences is developing cytisinicline as a treatment for nicotine dependence, with smoking cessation as the first proposed U.S. indication.
Achieve advanced cytisinicline toward an FDA decision, but losses and cash burn widened.
The read at a glance✓ Audited against SEC data
- Business mix — Cytisinicline for nicotine dependenceNote
- Revenue — No product revenue in local bundleNote
- Profitability — Net loss widened to $54.6MWatch
- Cash burn — Free cash flow was -$49.5MWatch
- Balance sheet — Equity +3.0% to $21.5MNote
- Insiders — 0 buys / 6 sellsWatch
- Accounting — Going-concern and contingent consideration riskWatch
Leadership changes
From ACHIEVE LIFE SCIENCES, INC.'s own filings, the day they're filed.
- Jeff Farrow · directors · appointmenteff. 2026-05-29
- Andrew Goldberg · Chief Executive Officer · appointmenteff. 2026-04-18
- Lucian Iancovici · Directors · appointmenteff. 2026-04-17
Latest filings
- 8-K · Company announcement2026-08-14
- 8-K · Company announcement2026-08-11
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-07-06
- DEF 14A · Annual proxy (pay & governance)2026-06-08
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ACHIEVE LIFE SCIENCES, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.